

Trust Headquarters Russells Hall Hospital Dudley West Midlands DY1 2HQ

Ref: FOI-082025-0001858

Date: 22.9.25

Address / Email:

Dear

Request Under Freedom of Information Act 2000

Thank you for requesting information under the Freedom of Information Act 2000, please see response below

I have a freedom of information request regarding the treatment of Multiple Myeloma. Could you please answer the following question.

Of the multiple myeloma patients over the past 6 month, how many were treated with the following:

Any other systemic anti-cancer therapy Belantamab Mafodotin [Blenrep] 0 Belantamab Mafodotin [Blenrep] with bortezomib and dexamethasone 0 Belantamab Mafodotin [Blenrep] with pomalidomide and dexamethasone 0 Bortezomib [Velcade] monotherapy or with dexamethasone 0 Bortezomib [Velcade], Melphalan/Cyclophosphamide and prednisolone/dexamethasone (VMp or VCd)
Belantamab Mafodotin [Blenrep] with bortezomib and dexamethasone Belantamab Mafodotin [Blenrep] with pomalidomide and dexamethasone Bortezomib [Velcade] monotherapy or with dexamethasone Bortezomib [Velcade], Melphalan/Cyclophosphamide and
Belantamab Mafodotin [Blenrep] with pomalidomide and dexamethasone Bortezomib [Velcade] monotherapy or with dexamethasone Bortezomib [Velcade], Melphalan/Cyclophosphamide and
dexamethasone Bortezomib [Velcade] monotherapy or with dexamethasone Bortezomib [Velcade], Melphalan/Cyclophosphamide and
Bortezomib [Velcade] monotherapy or with dexamethasone 0 Bortezomib [Velcade], Melphalan/Cyclophosphamide and
Bortezomib [Velcade], Melphalan/Cyclophosphamide and
predifisoione/dexametriasone (vivip or v Cd)
Bortezomib, thalidomide and dexamethasone [VTD] 0
Carfilzomib [Kyprolis] and dexamethasone 0
Carfilzomib [Kyprolis], Lenalidomide [Revlmid] and dexamethasone 0
Daratamumab [Darzalex] with Lenalidomide [Revlimid] and dexamethasone
Daratumumab [Darzalex] monotherapy 6
Daratumumab [Darzalex], Bortezomib [Velcade] and dexamethasone (known as DVd or DBd)
Daratumumab [Darzalex], Bortezomib [Velcade], thalidomide and dexamethasone (known as Dara-VTd)
Elranatamab 1
Idecabtagene vicleucel [Abecma] 0
Isatuximab [Sarclisa], Pomalidomide [Imnovid] and dexamethasone (known as IsaPd)
Ixazomib [Ninlaro], Lenalidomide [Revlmid] and dexamethasone (known as IRd)
Lenalidomide [Revlimid] and dexamethasone 28
Lenalidomide [Revlmid] monotherapy 7
Panobinostat in combination with Bortezomib and Dexamethasone 3

FOI/REF FOI-

Pomalidomide [Imnovid] and dexamethasone	5
Selinexor and dexamethasone	0
Selinexor, Bortexomiv [Velcade] and dexamethasone	1
Talquetamab	0
Teclistamab [Tecvayli]	2

If you are dissatisfied with our response, you have the right to appeal in line with guidance from the Information Commissioner. In the first instance you may contact the Information Governance Manager of the Trust.

Information Governance Manager Trust Headquarters Russell's Hall Hospital Dudley West Midlands DY1 2HQ

Email: dgft.dpo@nhs.net

Should you disagree with the contents of our response to your appeal, you have the right to appeal to the Information Commissioners Office at.

Information Commissioners Office Wycliffe House Water Lane Wilmslow Cheshire SK9 5AF Tel: 0303 123 1113

Tel: 0303 123 1113 www.ico.org.uk

If you require further clarification, please do not hesitate to contact us.

Yours sincerely

Freedom of Information Team
The Dudley Group NHS Foundation Trust